The Retin-A label says Retin-A is indicated for topical application in the treatment of acne vulgaris. Trial abstracts report tretinoin creams and gels compared with vehicle (a placebo) and with other products. Reviews also report adverse events and tolerability. Each result below belongs to the strength and product named.
What the label says
The label also says the safety and efficacy of long-term use in the treatment of other disorders have not been established. Neither statement names a strength. A label is not a trial.
What the trials measured
| Source and strength | Length, size, comparison and result |
|---|---|
| Double-blind, vehicle-controlled, multicenter trial of two tretinoin creams (J Am Acad Dermatol, 1998). Strength: 0.025%, from the paper's title; the abstract sentence about design does not state it. | 12 weeks, parallel group, patients with mild to moderate acne, 271 patients enrolled. Efficacy was judged by objective lesion counts and the investigators' global evaluations. The two active creams showed comparable efficacy that was statistically significantly greater than the vehicle. |
| Tretin-X compared with Retin-A (Skinmed, 2006). Strength: 0.1% cream (study 1) and 0.025% cream (study 2). | 1642 adolescents and adults, 12-40 years of age, with mild-to-severe acne, randomly assigned to Tretin-X, Retin-A, or placebo (drug vehicle), among other products. In each trial the two products were clinically equivalent on all primary and secondary end points at Weeks 2, 4, 8, and 12. That sentence does not state strengths and compares the two tretinoin products with each other, not with placebo. |
| JAMA review (2021) describing a randomized trial. Strength: tretinoin 0.025% gel (a gel, not a cream). | 207 patients, tretinoin as a single therapy. Acne lesion counts at 12 weeks were reduced by 63% compared with baseline. This is a change from baseline, not a comparison with vehicle. |
| Retrospective, investigator-blinded, vehicle-controlled photographic assessment (Clin Ther, 2005). Strength: tretinoin gel, not given in the result sentence. | Photographs came from patients in 12- or 15-week double-blind comparisons that included tretinoin 0.1% microsponge and tretinoin 0.025% gel. The difference in prevalence of clinically significant improvement was statistically similar between the tretinoin gel and vehicle groups. |
The 1998 trial reports efficacy greater than vehicle for 0.025% creams. The 2005 photographic assessment reports statistically similar improvement for a tretinoin gel and vehicle. The rows differ in product, design and measure, so they are not added together.
What reviews and the guideline report
- The abstract of the American Academy of Dermatology acne guideline (2024) states strong recommendations for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. It does not name tretinoin or any strength. Oral doxycycline is taken by mouth, unlike topical products.
- A systematic review of topical retinoids (Am J Clin Dermatol, 2019) reports no significant difference in efficacy between tretinoin and tazarotene, with no strength stated in that sentence. It also reports that tretinoin 0.05% resulted in 62% of patients experiencing adverse events (AEs), compared with adapalene 0.1% (19%) and adapalene 0.3% (40%). The sentence does not say what the events were.
- A network meta-analysis (Br J Dermatol, 2022) states that BPO (benzoyl peroxide) and topical retinoids were less well tolerated than placebo. It names a group of products, not a tretinoin strength.
- A Cochrane overview (2024) states that no review collected data for topical retinoids versus placebo or no treatment, among other comparisons. That is about what the reviews had collected. It does not say no trial made the comparison.
Rosacea, and when side effects are a reason to call
MedlinePlus says rosacea is a long-term disease that affects the skin and sometimes the eyes and causes redness and pimples. A licensed provider decides the diagnosis.
For people already using topical tretinoin, the patient instructions in the Retin-A cream and gel label state that if you are experiencing severe or persistent irritation, discontinue the use of Retin-A and consult your physician. The Twyneo label, for a cream that combines tretinoin and benzoyl peroxide rather than tretinoin alone, states to stop using Twyneo and get medical help right away if you have any of the following symptoms during treatment with Twyneo: hives, rash or severe itching, swelling of your face, eyes, lips, tongue, or throat.
What this does not tell you
Strengths differ across these sources, and some abstracts do not state one. A result at 0.025% is not a result at 0.05% or 0.1%. Trial numbers should not be compared with each other.
These are group results from abstracts. They do not say what any one person will see or choose a product or strength for anyone. A licensed provider decides that.
The FDA page Compounding and the FDA: Questions and Answers says compounded drugs are not FDA-approved, meaning FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. None of the results above shows the same strength, quality or result for a compounded cream.